Use of Combination Compounds for Inhibiting SARS-COV-2 (COVID-19) – Induced Cytokine Release

Categories: “”Viruses, Chronic & Infectious Diseases” 

Reference #: 2020-036

OTC Contact: Tracy Bruehs, M.S., J.D. (Directory Information | Send a Message)

INVENTION

Georgetown researchers propose a combined use of one or more compounds for prevention of COVID-19 mediated cytokine release syndrome, inhibiting the release of one or more cytokines, or inhibiting a cytokine storm, or preventing cytokine release syndrome or a cytokine storm.

APPLICATION

  • Prevent progression of neurodegenerative disorders such as multiple sclerosis (MS) by promoting re-myelination and thereby improving nerve conduction, acceleration, metabolic isolation etc.
  • Regulate inflammation in the central nervous system to create conditions necessary for regeneration
  • Treatments, prophylactics and prevention or inhibition of cytokine release syndrome, and cytokine storm induced by SARS-CoV-2 (COVID-19) and
  • Treatment to reduce elevated levels of cytokines as well as inflammation in a subject due to infection with SARS-CoV-2, aging, diabetes or obesity through the administering specific compositions comprised of:
    – One or more specific oxidized cofactor(s)/precursors that play a role in metabolism, in combination with or without:
    – One or more of a specific inhibitor(s) of certain genes, in combination with or without:
    – One or more specific agonist(s) that activates certain receptors.

ADVANTAGES

  • Possible treatment for COVID-19
  • Reduction, prevention or inhibition of cytokine release and/or cytokine storm in COVID-19 patients
  • Possible application to other diseases such as inflammation associated with aging, diabetes, and/or obesity
  • Kit comprising one or combination of co-factor precursors, inhibitor and agonists

BACKGROUND

COVID-19 causes a severe acquired respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with COVID-19 present with severe acute respiratory syndrome, which may progress to acute respiratory distress syndrome, cardiac abnormalities, gastrointestinal ailments, and renal complications among other short and long term ailments.  If infection from SARS-CoV-2 is not controlled, the innate immune response to the infection may lead to a biological response called cytokine release syndrome (CRS).  CRS occurs when large numbers of white blood cells are activated and release inflammatory cytokines, which in turn activate yet more white blood cells.  Such a release of cytokines, or “cytokine storm,” can overwhelm the body and potentially lead to fatality.  This potential therapy that can effectively prevent a cytokine storm in those suffering from SARS-CoV-2 infection. This technology offers a method of administrating a combination of several compositions as a potential treatment.

STAGE OF DEVELOPMENT

In vitro and in vivo studies currently underway, preliminary

PATENT STATUS

PCT/US2021/033801

INVENTOR

Moshe Levi, MD